Abbott Sheds Criminal Cloud, But Civil Storm Looms Large

Key Takeaways

• The U.S. Justice Department's decision to close its criminal probe into Abbott Laboratories' baby formula plant significantly de-risks the company from a major regulatory overhang.
• Despite this relief, Abbott faces a substantial and escalating civil litigation battle over its infant formula, with recent multi-million dollar jury verdicts and over 1,700 lawsuits pending.
• While Wall Street analysts maintain a "Buy" consensus with considerable upside, investors must weigh Abbott's robust financial performance and innovation in diagnostics against the unpredictable financial and reputational costs of ongoing civil liability.

The Criminal Cloud Lifts, But the Legal Storm Rages On

Abbott Laboratories (NYSE: ABT) shareholders breathed a collective sigh of relief on June 28, 2026, as news broke that the U.S. Justice Department had formally closed its criminal investigation into the company's baby formula plant. This development, reported by the Wall Street Journal, removes a significant Sword of Damocles that has hung over the medical device and healthcare giant since its Sturgis, Michigan, facility was linked to infant illnesses and deaths in 2022. The closure of the criminal probe, which had considered misdemeanor charges for violating the federal Food, Drug and Cosmetic Act and misleading the government, shifts the DOJ's focus to civil penalties, a considerably lighter outcome than criminal prosecution.

The market's initial reaction to such news can often be a sharp upward re-rating, reflecting the removal of existential risk. Abbott's shares, currently trading at $93.82, have seen a 52-week range spanning from a low of $81.97 to a high of $137.49. While the criminal probe's closure is undoubtedly a positive, it's crucial for investors to understand that this does not signal a clear path forward. As a spokeswoman for the DOJ told the Wall Street Journal, "Ensuring the safety of our nation's food supply is a top priority for the Trump administration; however, this Department of Justice does not believe in regulation by prosecution." This statement suggests a policy decision rather than a complete exoneration of Abbott's past conduct. Indeed, the company remains embroiled in a complex web of civil lawsuits, which present a distinct and potentially more tangible financial threat.

Solid Growth Amidst Legal Headwinds

Beyond the legal headlines, Abbott Laboratories continues to demonstrate a strong operational footing, driven by its diversified portfolio across diagnostics, medical devices, nutrition, and pharmaceuticals. The company reported robust first-quarter 2026 results on April 16, 2026, showcasing its ability to generate growth even while navigating significant external pressures.

For the first quarter ended March 31, 2026, Abbott reported adjusted diluted earnings per share of $1.15, surpassing expectations. Revenue for the quarter reached $11.2 billion. Looking ahead, the company projects second-quarter 2026 adjusted diluted earnings per share to be in the range of $1.25 to $1.31. Management also updated its full-year 2026 guidance, anticipating comparable sales growth of 6.5% to 7.5%. This growth trajectory is bolstered by strategic moves, including the completed acquisition of Exact Sciences in the first quarter, which positions Abbott as a leader in the rapidly expanding oncology diagnostics market.

Abbott's commitment to shareholder returns also remains a cornerstone of its capital allocation strategy. The company declared its 409th consecutive quarterly dividend of $0.63 per share on February 20, 2026, payable on May 15, 2026. This translates to a current dividend yield of 2.63%, a testament to its Dividend King status and consistent cash flow generation. The steady dividend, alongside strategic acquisitions like Exact Sciences, underscores a company that is actively managing its business for long-term value creation, even as it grapples with the complexities of its legal environment.

The Lingering Shadow of NEC Lawsuits

While the criminal probe's conclusion offers a measure of relief, the more immediate and financially impactful challenge for Abbott lies in the ongoing civil litigation surrounding its cow's milk-based infant formulas and their alleged link to necrotizing enterocolitis (NEC) in premature infants. This is not a distant threat; it is a present reality with significant financial implications.

A major bellwether trial began in Cook County, Illinois, on March 5, 2026, involving claims from four families alleging Abbott's formula caused NEC in their premature babies. The outcomes of such trials are closely watched, as they often set the tone for future settlements or verdicts. Indeed, on April 10, 2026, a Cook County jury awarded $53 million in compensatory damages against Abbott in a case involving four mothers. The following day, on April 11, 2026, the jury added an additional $17 million in punitive damages, bringing the total verdict to a staggering $70 million. These substantial awards highlight the serious financial exposure Abbott faces.

The scale of this litigation is immense. Abbott and Mead Johnson currently face more than 750 Similac and Enfamil lawsuits consolidated in a federal multidistrict litigation (MDL) in the Northern District of Illinois, with the number of cases growing to 775 by February 2026 and over 1,700 total lawsuits across federal and state courts. A second wave of bellwether trials is already scheduled to begin in August 2026, indicating that this legal battle is far from over. Abbott has consistently denied that its products cause NEC, stating that "there was no evidence linking its formulas to these illnesses," and that "no unopened, distributed Abbott infant formulas have tested positive for the bacteria that sickened the babies," according to a company spokesman who spoke to the Wall Street Journal. The company has also indicated its intent to appeal adverse verdicts.

The stakes are high. In December 2025, Abbott even launched an aggressive lobbying campaign, warning it might be "forced" to withdraw certain preemie products from the market if Congress did not grant significant legal protections. This move underscores the severity of the perceived liability and the potential for market disruption if the litigation continues to escalate without a broader resolution.

Innovation and Capital Allocation Drive Future Prospects

Beyond the legal challenges, Abbott's core business remains a powerhouse of innovation and strategic capital deployment, positioning the company for long-term growth. The recent acquisition of Exact Sciences, completed in the first quarter of 2026, is a prime example of this forward-looking strategy. This deal significantly expands Abbott's footprint in the oncology diagnostics market, a sector characterized by high growth and unmet medical needs. Integrating Exact Sciences' advanced diagnostic capabilities into Abbott's existing portfolio is expected to create synergies and accelerate product development, particularly in areas like early cancer detection.

Abbott's medical device segment, which includes its FreeStyle Libre continuous glucose monitoring system, continues to be a key growth driver. Expanding access to these devices and launching new product iterations are critical catalysts. The company's pipeline across its various segments—from cardiovascular devices to established pharmaceuticals—demonstrates a consistent commitment to R&D and bringing new solutions to market. This diversified approach helps to mitigate risks associated with any single product or market segment.

Furthermore, Abbott's consistent dividend policy, marked by its 409th consecutive quarterly dividend, reflects a disciplined approach to capital allocation. This commitment to returning capital to shareholders, alongside strategic investments in growth, signals management's confidence in the company's underlying financial strength and future cash flow generation. While the legal landscape presents a challenge, Abbott's ability to innovate and allocate capital effectively remains a fundamental pillar of its investment thesis.

The Bear Case: Escalating Civil Liability and Reputational Damage

Despite the relief from the criminal probe, the bear case for Abbott Laboratories remains firmly rooted in the escalating civil litigation over its infant formula. The potential for substantial financial penalties and lasting reputational damage cannot be overstated. The $70 million verdict in Cook County in April 2026 serves as a stark reminder of the financial exposure. With over 1,700 lawsuits pending, even a fraction of similar outcomes could lead to billions in liabilities.

The unpredictable nature of jury verdicts, coupled with the sheer volume of cases, makes it difficult to model the ultimate financial impact. While Abbott plans to appeal, the legal process is lengthy and costly, diverting resources and management attention. Even if a global settlement is eventually reached, it is likely to be a multi-billion dollar affair, impacting future earnings and cash flow. The December 2025 warning from Abbott about potentially withdrawing preemie formula underscores the company's concern about the financial viability of these products under current legal pressures.

Beyond direct financial costs, the ongoing litigation carries significant reputational risk. The narrative of infant illnesses and deaths associated with a core product can erode consumer trust, particularly in the sensitive nutrition segment. This damage can be long-lasting, potentially affecting sales of other Abbott products and making it harder to attract and retain talent. Furthermore, while the criminal probe is closed, other regulatory bodies, such as the SEC and FTC, have previously launched their own investigations into Abbott's infant formula business and WIC contracts, as reported in February 2023. Although these are distinct from the DOJ's criminal case, they indicate a broader regulatory scrutiny that could lead to further civil penalties or operational restrictions. The FDA's previous findings of "egregiously unsanitary conditions" at the Sturgis plant, as described by FDA chief Dr. Robert Califf in May 2022 congressional testimony, continue to serve as a potent reminder of past operational deficiencies that could be leveraged in civil proceedings.

Wall Street Sees Upside, With Caveats

Wall Street analysts generally maintain a constructive view on Abbott Laboratories, despite the legal overhangs. The consensus rating among 41 analysts is a "Buy," with 31 analysts recommending Buy and 10 recommending Hold. There are no Sell or Strong Sell ratings, indicating a broadly positive sentiment.

The average analyst price target for ABT stands at $126.00, with a median target of $123.50. This median target implies a significant upside of 31.6% from the current price of $93.82. The range of price targets is wide, from a low of $92.00 to a high of $152.00, reflecting differing views on the company's growth prospects and the potential impact of its legal challenges. Recent rating actions include Piper Sandler maintaining an "Overweight" rating on June 22, 2026, and BTIG maintaining a "Buy" rating on April 27, 2026.

Analysts are likely factoring in Abbott's strong underlying business performance, diversified revenue streams, and consistent innovation in medical devices and diagnostics. The closure of the criminal probe removes a major tail risk, which could lead to upward revisions in price targets, especially from those who had previously assigned a higher discount for this specific legal uncertainty. However, the ongoing civil litigation and its potential financial repercussions are likely to remain a key point of discussion and a source of caution for analysts, with the low end of the price target range reflecting the possibility of adverse outcomes. Investors will be closely watching the upcoming earnings report on July 16, 2026, for further insights into management's outlook.

The Verdict: Navigating a De-Risked but Still Challenged Giant

Abbott Laboratories stands at a critical juncture. The closure of the U.S. Justice Department's criminal probe is a definitive positive, removing a severe, albeit unlikely, worst-case scenario. This de-risking event should provide a floor for the stock and allow investors to refocus on Abbott's robust operational performance and innovation pipeline, particularly in high-growth areas like oncology diagnostics through its Exact Sciences acquisition. However, the shadow of civil litigation, marked by recent multi-million dollar verdicts and a vast number of pending lawsuits, remains a formidable and unpredictable challenge. The market must now grapple with the tangible financial and reputational costs of these ongoing battles.

For investors with a higher risk tolerance and a long-term horizon, the current valuation presents an opportunity to enter a high-quality, diversified healthcare leader at a discount, post-criminal probe. We recommend an entry zone between $90.00 and $95.00 per share, capitalizing on any lingering apprehension from the civil litigation. Our 12-month target price is $120.00, reflecting the company's strong fundamentals and the removal of the criminal overhang, while still accounting for the ongoing civil liabilities. An invalidation level of $85.00 per share would signal a significant deterioration in the civil litigation outlook or unexpected operational setbacks, warranting a re-evaluation of the thesis. Abbott's journey ahead will be defined by its ability to continue innovating and growing, even as it navigates the persistent, costly, and complex civil legal storm.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.